BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GSK4771261 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GSK4771261\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07600450-11193@assetmemo.bio
DTSTAMP:20261121T005734Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:GSK4771261: Phase 1 readout est. (NCT07600450)
DESCRIPTION:GSK4771261\, phase 1.\nStudy: A Study of GSK4771261 in Healthy 
 Participants Aged 25 to 55 Years of Age Inclusive\nEstimated primary compl
 etion: 20 May 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/g
 sk4771261#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07600450
URL:https://assetmemo.bio/drug/gsk4771261#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734234-11193@assetmemo.bio
DTSTAMP:20261121T005734Z
DTSTART;VALUE=DATE:20270723
DTEND;VALUE=DATE:20270724
SUMMARY:GSK4771261: Phase 1 readout est. (NCT06734234)
DESCRIPTION:GSK4771261\, phase 1\, Autosomal Dominant Polycystic Kidney Dis
 ease.\nStudy: A Study to Evaluate the Safety\, Tolerability\, and Effects 
 on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healt
 hy Participants and Participants With Autosomal Dominant Polycystic Kidney
  Disease\nEstimated primary completion: 23 July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/gsk4771261#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06734234
URL:https://assetmemo.bio/drug/gsk4771261#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
